Microsaic Systems Share Discussion Threads

[guyswonga74] 18/12/2017 08:33

Now 2.8p to buy

[babbler] 18/12/2017 08:03

Got more. Down as a sell.

[guyswonga74] 18/12/2017 07:17

This certainly is cheap, can see a big blue day today

[barnetpeter] 17/12/2017 22:02

This is cheap...no doubt. Easy 5p here. Lets see if any of us can buy more stock in the morning. I doubt it will be easy.

[guyswonga74] 17/12/2017 21:59

Why the jump to 2.8p moments after the bell Friday. Must be a big buy which hasn't been disclosed by mms yet

[the big fella] 17/12/2017 21:04

Simple they walked this down to flush out the weak sellers covering the stock they had sold plus 4p. The chart is set for further gains next week. Higher highs and higher lows.

[kingston78] 17/12/2017 21:03

There is a saying "go with the flow". It holds true throughout centuries.

It is no good to be stubborn and sticking to a limit. What appears to be expensive now may seem cheap later.

Buy high, sell higher is my motto.

[tomboyb] 17/12/2017 20:56

It has been hard buying or selling for that matter when MMs want -

Lowest that was available a few days back was below 1.7p -

However it was impossible to buy even though I saw trades going through -

1.75p was 100k max online and trading 250k at 1.82 ( which went quickly ) and between 1.9 and 2.1p -

There were a good few available 1.9-2.1p but that now looks to be gone -

A bit of patience may well pay dividend -

[guyswonga74] 17/12/2017 20:34

Casino going on last years cash burn I estimate it's just over 3 million in the bank. I suspect the big pharma will be funding future r&d. Can see a mass scar le to buy in first thing

[casano] 17/12/2017 20:00

Barn - what you trying to say is that company should Roman placing, just to let PIs be able to buy! That’s just one of most outrageous reason for a placing next. I’ve ever heard! Company has no reason to dilute, as they have over £4M waiting in the bank. GLA

[barnetpeter] 17/12/2017 19:29

I got some at 1.77 I think but always via a broker. Online trading is usually turned off. See discussion above....just no stock here,

[babbler] 17/12/2017 18:21

I guess they didn't do much promotion before as the product wasn't mature enough. Now that it is turnaround has begun. THE share to own next year (well one of 10 great shares)

[babbler] 17/12/2017 18:18

Not really. I tried a couple of times. Not much available. Unless taking 800 or less.

[guyswonga74] 17/12/2017 18:01

Was it easy to buy at 2p or under late Thursday?

[tomboyb] 17/12/2017 14:51

Those that were selling at below 1.7p now could of had a 50% -70% rise or more -

Clearly with that news that selling was a opportunity to add more -

[guyswonga74] 17/12/2017 14:48

Certainly see it testing 5p by Tuesday. Lots of interest here

[kingston78] 17/12/2017 11:18

What is more significant from a technical perspective is that the chart has now broken the long term downtrend. The scope of an upward rise is phenomenal. In due course it has the capability of reclaiming the lost ground back in April 2015 when the share price was at 50 p.

I expect a very short term target of 10 p and then 20 p within three months.

By way of comparison, PYC rose from 1 p to 30 p within a week before stabilising at around 11 p. VAL went up from under 1 p to 7 p in short order. There is no reason why MSYS could not do the same.

[guyswonga74] 17/12/2017 10:59

Around 3 million cash in bank and deal with a multimpharma. Sp is not much more then cash. Small free float. Could triple by next week

[guyswonga74] 17/12/2017 10:39

I suspect there will be a rush to buy at the open. As this is a volatile share with a free float of 40 million it could spike early. I can see this testing the 4.4p high tomorrow

[moneymunch] 16/12/2017 19:53

28/9/17

OUTLOOK

The Board sees significant opportunities for its MS instruments being integrated into multiple areas of bioprocessing, and for diagnostics in the longer term.

The Company is transforming the way it operates. It has a vision to help solve some of the major problems in human health. To do this, the Company aims to work with global partners with similar aspirations, which are prepared to co-fund R&D development costs and ensure that new product opportunities are adequately validated so they meet customer needs.

The Company expects its full year 2017 revenue to be significantly lower than 2016. The shortfall in revenue is expected to be off-set by lower overheads as a result of cost reduction plans implemented in H1 2017 and that the full year loss before tax will be broadly in line with 2016. Progress has been made in addressing the difficult trading conditions and H2 2017 revenues are anticipated to be above H1 2017 based on current Q3 performance.

[guyswonga74] 16/12/2017 19:16

Cash burn last year was 1.3 million so I would say just over 3 million cash left